Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eque-cel in Relapsed/Refractory SLE
NCT06902844Phase 1Recruiting
- Sponsor
- Tongji Hospital
- Start
- Apr 2025
- Primary completion
- Oct 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of equecabtagene autoleucel in systemic lupus erythematosus (SLE), sponsored by Tongji Hospital. Primary endpoint: SLE Responder Index-4 Response Rate at 6 months. Started Apr 2025; status: recruiting.
02
Drugs
equecabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06902844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06902844.